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BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSV) confer elevated risks of 
multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. 
Knowledge of the PSV distribution in African descent individuals is poorly understood. We 
undertook a systematic review of the published literature and publicly available databases 
reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 
(CIMBA) database to identify African or African descent individuals. Using these data, we inferred 
which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 
PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African 
descent individuals were identified in public databases (n=291) and the literature (n=601). We 
identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of 
these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed 
numerous differences in the distribution of PSV type and function in African origin vs. non-African 
origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to 





Many women benefit from genetic testing information that can guide their knowledge of cancer 
risks and help them to make informed prevention and medical management decisions if they have 
inherited pathogenic sequence variants (PSV) in BRCA1 (GenBank reference sequence: 
NG_005905.2)  or BRCA2 (GenBank reference sequence NG_012772.3) (BRCA1/2). Knowledge 
of genetic risk is valuable because it can lead to the use of risk-reducing salpingo-oophorectomy 
or bilateral mastectomy, which significantly decrease breast and/or ovarian cancer risk and 
mortality BRCA1/2 PSV carriers[1-7]. However, the vast majority of information about cancer risk 
and risk reduction has to date been conducted in Caucasian and Ashkenazi Jewish women[8].  
Because there has been limited capture of BRCA1/2 PSVs in more diverse race/ethnicity groups, 
we anticipate that a large number of PSVs have yet to be reported. Similarly, there is very limited 
information about cancer risks and the effect of prevention strategies in non-White/non-Jewish 
women. Therefore, a better understanding of PSVs and cancer risks in underrepresented 
populations is a critical unmet need in the BRCA1/2 field. 
The BRCA1/2 International Diversity by Geography and Ethnicity (BRIDGE) Study has been 
developed to provide information about BRCA1/2 PSVs in populations who are currently 
underrepresented in research. We characterize PSVs in self-reported African ancestry (SRAA) 
individuals identifying commonly-reported PSVs that may have had their origins on the African 
continent and identify potential African founder PSVs and PSV hot spots.  
 
Methods 
The individuals included in this analysis were inferred to have African ancestry based on self-
report or inference based on place of birth or residence. We included Africans from sub-Sahara 
Africa and black South Africans. We also included those reporting African origins from North 
America, South America, the Caribbean, Europe, or Asia. We excluded White (Afrikaners) and 
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Asian South Africans, mixed race (Coloured) South Africans, and individuals who self-reported to 
be of other race/ethnicity groups whose ancestral origins were from outside Africa (e.g., Asian 
and middle eastern) and North Africans (Morocco, Tunisia, Algeria, Libya, and Egypt). In addition, 
this report only includes females with PSVs. In some cases, the basis of the race/ethnicity 
determination was not stated in the original research, and the assumption was made that the 
source of race/ethnicity information was by self-report or determined by the research team. None 
of the information about race or ethnicity was based on ancestral genomic information.  
 
To characterize the distribution of PSVs in SRAA individuals, we evaluated a series of data 
sources (Figure 1). First, we undertook a systematic literature review of published studies 
reporting a deleterious BRCA1/2 PSV in an individual of SRAA, including sub-Saharan Africa, 
Caribbean, and African American. To identify reports of BRCA1/2 PSVs in SRAA individuals, we 
used the following key words to search the medical literature: BRCA1 or BRCA2 and Africa or 
African (includes African American), or Caribbean. Each paper was reviewed to determine if it 
described an independent study done in SRAA individuals and reported the presence of a 
disease-associated PSV in BRCA1/2. PSVs reported in other genes were excluded. Reports of 
PSV testing for BRCA1/2 that reported no disease-associated PSVs were not included in this 
report. Reports of variants of unknown significance were also excluded. All studies were included 
regardless of sampling design (e.g., family studies, population screening, genetic testing in clinical 
case series, etc.). In addition, a small number of papers or abstracts were identified from the 
citation list of the papers that were identified from the public literature search. 
 
Second, we obtained data from the CIMBA consortium[9] using the coded ethnicity variable for 
African American and countries in Sub-Saharan Africa, which included reports from Nigeria and 
South Africa only. White South Africans, Afrikaners, and mixed-race (Coloured) South Africans 
were excluded.  
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Third, we used publicly available data from the BIC (https://research.nhgri.nih.gov/bic/) database. 
A copy of the BIC database was downloaded on February 1, 2019 to identify reported BRCA1/2 
PSV carriers. The ethnicity and nationality variables were searched for any notation of African 
descent individuals, African, African American, or Caribbean.  
 
Lastly, the NIH public database ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) was used as a 
check for PSV nomenclature and confirmation of the pathogenic status of each variant. CIMBA 
and BIC, among other sources, submitted their PSVs to ClinVar. The majority of sources did not 
contribute race/ethnicity information to ClinVar, so this database was determined not to be a 
useful data source for this report.  Most PSVs reported here have been deposited into the ClinVar 
database. 
 
PSVs were categorized according to type and function, including large deletion (DL), large 
duplication (DP), frameshift (FS), in-frame deletion (IFD), missense (MS), nonsense (NS), splice 
(SP), and individuals who carried multiple PSV types (including those listed above); No RNA, 
Premature Termination Codon (PTC), Nonsense-Mediated Decay (NMD), NMD with or without 
re-initiation; and mutation class (1, 2, or 3).  
 
To establish the continental origin of BRCA1/2 PSVs that were reported in SRAA individuals, we 
identified PSVs reported in regions in which non-African admixture was likely (i.e., North America, 
Caribbean, South America, South Africa) and where non-African admixture was less likely (i.e., 
Sub-Saharan Africa excluding South Africa). Supplementary Table 1 presents PSVs reported 
only in Sub-Saharan Africa and PSVs reported only in the Americas. In addition, we evaluated 
whether any of these PSVs were reported in non-African ancestry groups (e.g., Europeans or 
European Americans). We judged a PSV to be likely African origin if the PSV has only been 
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reported in SRAA and never in a non-SRAA individual, and of possibly African origin if reported 
greater than 50% of the time in SRAA individuals. This inference was strengthened by the 
observation of a PSV reported in Africa. We judged the PSV to be likely non-African origin if it 
reported less than 50% of the time in SRAA individuals.   
 
Collection of original data was undertaken under approved research and/or clinical human 
subjects protocols at each contributing center. Retrospective anonymized data analysis for the 
present research was undertaken under human subjects approvals at the Dana-Farber Cancer 
Institute. 
Results 
African Ancestry Individuals with BRCA1/2 PSVs 
The results of our literature search are shown in Figure 1. When more than one paper from a 
research group was found, we included the largest or most recent in the series. Studies that 
searched for but did not find any BRCA1/2 PSVs in SRAA women were excluded. Note that only 
eleven published studies were found that included male BRCA1/2 PSV carriers, but no additional 
BRCA1/2 PSVs were identified from these reports. 48 studies were included in the present report: 
16 studies of Sub-Saharan Africans[10-25], 27 of African Americas[13, 26-54], and 3 of Afro-
Caribbean populations[55-57] and one study reporting SRAA of unspecified geography [49]. From 
these papers, we identified 414 BRCA1 and 187 BRCA2 PSVs, and 108 unique BRCA1 and 103 
unique BRCA2 PSVs. 
 
The BIC database included 15,311 total submissions of BRCA1 PSVs, of which 8,564 were 
reported to be pathogenic. Of these, 206 (2.4%) were identified as SRAA. The BIC database 
included 14,914 total submissions of BRCA2 PSVs, of which 4,516 were deleterious. Of these, 
85 (1.9%) identified as SRAA.  
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The CIMBA database consisted of 43,817 BRCA1/2 female PSV carriers.  Of these, 382 (0.9%) 
were identified as African Americans and 269 (0.6%) were ascertained in Africa. Thirty-two of 
these carriers were from Nigeria and 237 were from South Africa.  After excluding White South 
Africans, Afrikaaners, or mixed-race (Coloured) South Africans, 11 black South Africans were 
included. In total, 435 (1%) women of African descent were found in the CIMBA database. Of 
these 273 were BRCA1 and 162 were BRCA2. In addition, 34 African American carriers from the 
University of Illinois at Chicago, 14 BRCA1 and 20 BRCA2, not previously reported to CIMBA, 
were also included in the CIMBA dataset after consultation with the University of Illinois center. 
 
BRCA1/2 PSVs in African Ancestry Individuals 
Supplementary Table 1 presents the complete list of all SRAA PSVs identified in this study and 
relevant characteristics according to PSV designation, type, and function as well as where and in 
what populations they have been reported. From our 3 primary data sources, a BRCA1 PSV in 
SRAA was reported 909 times: 404 (44.3%) in African Americans, 170 (18.6%) in Africans, 135 
(14.8%) in the Caribbean, and 200 (21.9%) in SRAA of unknown or unreported geographic origin. 
From all data sources, we identified 164 unique BRCA1 PSVs. For BRCA2 a PSV in a woman of 
SRAA was reported 454 times, 262 (57.7%) in African Americans, 114 (25.1%) in Africans, 35 
(7.7%) in the Caribbean and 43 (9.5%) in SRAA of unknown origin.  Of these, we identified 173 
unique BRCA2 PSVs. We were not able to determine if an individual was included more than 
once in these data sources, so these figures do not represent the actual frequency of PSVs 
expected in SRAA. 
 
The most commonly identified PSVs in BRCA1 and BRCA2 are presented in Table 1. Most of 
these PSVs have been reported in multiple geographical locations, and in particular most have 
been reported in both the new and old world.  A small number of PSVs to date (n=39) have been 
reported only in Africans residing in Africa.  
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In order to identify PSVs that were most likely to be of African origin, we characterized PSVs 
according to the number of times they were reported in individuals of African and non-African 
descent (Table 2). We characterized those being reported only in SRAA populations and/or only 
in Africa as being of likely African origin (n=115), those reported >50-99% as possibly African 
origin (n=59), those 25-50% as probably non-African (n=35), and those reported <25% of the time 
in SRAA individuals as likely non-African origin (n=128). For BRCA1, 50 (30.5%) PSVs are likely 
to be of African origin, 33 (20.1%) possibly of African origin, 19 (11.6%) probably non-African, and 
62 (37.8%) likely of non-African origin. For BRCA2, 65 (37.6%) PSVs are likely to be of African 
origin, 26 (15.0%) possibly of African origin, 16 (9.2%) probably non-African, and 66 (38.2%) likely 
of non-African origin.  The list of these PSVs and their corresponding designations is presented 
in Supplementary Table 1.  Thus, about half of PSVs identified in SRAA can be inferred to be of 
likely or possibly African origin. 
 
Figures 2 and 3 display the frequency and distribution of likely or possible African origin PSVs 
across the span of each gene. For BRCA1, two common PSVs (c.5324T>G and c.4357+1G>A) 
were observed in multiple populations of African descent.  Among those identified as unlikely to 
be of African origin include the c.68_69del Jewish founder PSV, as well as PSVs that have been 
reported as common or founder PSVs in European populations (e.g., c.211A>G in Spain and 
c.5251C>T in Greece[58]) or in the CIMBA database (e.g., c.1504_1509del in Asians in Australia 
and c.5177_5180del in French Caucasians). Notably, the c.68_69del PSV was found in an African 
population in Burkina Faso[24] as well as many other populations in Europe, the Middle East, and 
North Africa. In BRCA2, c.5616_5620del was observed in multiple African descent populations. 
As with BRCA1, the most common PSVs that were inferred as unlikely to be of African origin have 
been reported as common or founder PSVs in European populations (e.g., c.2808_2811del in 
Spain and c.1310_1313del in Denmark, or in the CIMBA database (e.g., c.658_699del in 
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Germany and c.9382C>T globally, including Japan and in the CIMBA database in Europe) [58, 
59]. 
 
Using the SRAA CIMBA PSV carriers we were also able to characterize the distribution of PSVs 
by type and effect (Tables 3 and 4). FS, PTC and NMD were less common in SRAA than in 
CIMBA overall for both BRCA1 and BRCA2. IFD was more common in BRCA1 SRAA (but this 
included very few PSVs), and PSV class was different between SRAA and non-SRAA in BRCA2. 
For BRCA1, large deletions and duplications were not significantly different in frequency in CIMBA 
SRAA versus the previously reported CIMBA distribution[8].  There was also no significant 
difference for splice variants, PSV class, or lack of nonsense mediated decay (NMD) with re-
initiation, and marginally significant differences with missense PSVs, nonsense PSVs, no RNA, 
or re-initiation.  Other PSV types or functions included frameshift, in-frame deletions, PSVs of 
multiple types, premature termination codon, and NMD.  There were also significant differences 
in the number of PSVs with unknown PSV effect.  There were approximately twice as many SRAA 
PSVs of unknown effect than in other groups. 
 
For BRCA2, there were significant differences between SRAA and the published CIMBA PSV 
distribution for large deletions, frameshift, in-frame deletions, missense, and multiple PSV types.  
There were also statistically significant differences for all PSV effects including premature 
termination codon PSVs, NMD, and PSV class.  Again, the proportion of PSVs of unknown effect 
was significantly higher in SRAA than CIMBA as a whole.  
 
Discussion 
Despite the availability of substantial information regarding cancer risks in BRCA1/2 PSV carriers, 
the amount of information available to women of African ancestry is extremely limited.  The 
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worldwide CIMBA database containing over 30,000 families with BRCA1/2 PSVs includes less 
than 1% individuals of African ancestry[60].  This very limited capture of PSVs in women of African 
ancestry presents a number of important limitations for the clinical implementation and decision-
making for African ancestry women[44, 61].  
 
We summarize all reported PSVs found in SRAA individuals and infer which of these PSVs may 
be of African origin. Approximately half of PSVs reported in SRAA are likely or possibly of African 
origin. A number of individuals who are SRAA have inherited PSVs of European origin.  These 
PSVs were observed primarily in individuals in North America or the Caribbean and likely reflect 
recent European admixture.  However, the c.68_69del PSV was also commonly observed in all 
SRAA populations. Haplotype analyses suggest that this PSV arose no more than 1500 years 
ago, suggesting that it was transmitted from the middle east to Africa, and did not arise there 
before the original migration of individuals out of Africa[62]. However, this PSV has been reported 
in native Africans[24] and has arisen in multiple populations independently, so it is not known 
whether this PSV is a new PSV at a locus that demonstrates high mutation rates, or if it is the 
common Jewish founder PSV, which has been observed in Middle Eastern or North African 
populations[24, 62, 63].  
 
We also report that the distribution of PSV type or effect differs for some PSV groups between 
SRAA and the CIMBA population as a whole. It is well established that African women as well as 
African American women have an earlier average age of diagnosis and a higher proportion of 
hormone receptor negative and triple negative tumors than women of other ethnicities[64, 65].  It 
is not clear how much of this phenotypic pattern in African descent women could be explained by 
PSVs in BRCA1/2, but it is possible that, at least in Africa, a substantial proportion of breast 
cancer may be hereditary in nature. To the degree this is true, the observation in this report that 
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the distribution of PSV type or effect may be different in African descent populations compared 
with other populations could have clinical implications for assessing cancer risk in women of 
SRAA.  It is also possible that the penetrance associated with mutations in SRAA is different than 
that of non-SRAA populations.  However, the currently available data do not allow us to evaluate 
the relationship of PSVs in BRCA1/2, as well as specific types of PSVs, in cancer susceptibility.  
Reports in the literature do not provide consistent information about individual women and their cancer 
status that would be required to undertake association studies. Such associations could be undertaken 
in the CIMBA study, but the sample size of SRAA in the CIMBA data set remains underpowered for 
these analyses. In addition, the relatively larger proportion of PSVs that could not be characterized 
with respect to their effect compared with all PSV carriers suggests that additional research is 
required to understand the phenotypic consequences of BRCA1/2 PSVs in SRAA. 
We have also made initial ad hoc inferences about the likelihood that each PSV reported in SRAA 
is of African origin. We used a value of 50% of PSVs being observed in SRAA to suggest that the 
PSV was of African origin. However, given that the number of individuals tested for BRCA1/2 is 
much higher in non-Africans, it is possible this number is too conservative. If a PSV exists in both 
African women and non-African women regardless of percentage, the PSV may have arisen prior 
to the initiation of migration out of African 200,000-300,000 years ago. Mutations found only in 
SRAA women may represent new mutations that arose in Africa (i.e., since the migration out of Africa) 
or arose in populations that did not migrate out of Africa. In the future, estimation of haplotype 
backgrounds and PSV age will be important to further characterize the origin of PSV with respect 
to African vs. non-African origin.  
 
It is clear from our findings that there is a great need for increased participation among currently 
underserved populations in BRCA1/2 research.  Large-scale genomic studies of BRCA1/2 in 
Africa have yet to be undertaken, although initiatives such as H3Africa 
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(https://h3africa.orginitiative) may provide relevant data in the future if BRCA1/2 testing is 
undertaken by participating groups. Participation of these groups in BRCA1/2 research will 
provide a more comprehensive evaluation of PSVs in non-European descent populations and 
improve risk assessment and an understanding of risk modifiers. It will be critical to evaluate in 
these groups the complete PSV spectrum, common/founder PSVs (that may aid in developing 
efficient genetic testing panels) and understand the origins of these PSVs through 
population/evolutionary genetics research.  Additional research will be required to understand 






CIMBA: The CIMBA data management and data analysis were supported by Cancer Research – 
UK grants C12292/A20861, C12292/A11174. ACA is a Cancer Research -UK Senior Cancer 
Research Fellow. GCT and ABS are NHMRC Research Fellows. iCOGS: the European 
Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-
2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, 
C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National 
Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 
CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence 
(W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in 
Familial Risks of Breast Cancer (CRN-87521), and the Ministry of Economic Development, 
Innovation and Export Trade (PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer 
Research Foundation, and the Ovarian Cancer Research Fund. The PERSPECTIVE project was 
supported by the Government of Canada through Genome Canada and the Canadian Institutes 
of Health Research, the Ministry of Economy, Science and Innovation through Genome Québec, 
and The Quebec Breast Cancer Foundation.  
BCFR: UM1 CA164920 from the National Cancer Institute. The content of this manuscript does 
not necessarily reflect the views or policies of the National Cancer Institute or any of the 
collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade 
names, commercial products, or organizations imply endorsement by the US Government or the 
BCFR. BFBOCC: Lithuania (BFBOCC-LT): Research Council of Lithuania grant SEN-18/2015. 
BIDMC: Breast Cancer Research Foundation. BMBSA: Cancer Association of South Africa (PI 
Elizabeth J. van Rensburg). CNIO: Spanish Ministry of Health PI16/00440 supported by FEDER 
funds, the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R  and 
the Spanish Research Network on Rare diseases (CIBERER). COH-CCGCRN: Research 
 18 
reported in this publication was supported by the National Cancer Institute of the National 
Institutes of Health under grant number R25CA112486, and RC4CA153828 (PI: J. Weitzel) from 
the National Cancer Institute and the Office of the Director, National Institutes of Health. The 
content is solely the responsibility of the authors and does not necessarily represent the official 
views of the National Institutes of Health. CONSIT: Associazione Italiana Ricerca sul Cancro 
(AIRC; IG2014 no.15547) to  P. Radice.  Italian Association for Cancer Research (AIRC; grant 
no.16933) to L. Ottini.  Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. 
Peterlongo. Jacopo Azzollini is supported by funds from Italian citizens who allocated the 5x1000 
share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, 
according to Italian laws (INT-Institutional strategic projects ‘5x1000’). Dana-Farber Cancer 
Institute: NIH 5U54CA156732-07. DEMOKRITOS: European Union (European Social Fund – 
ESF) and Greek national funds through the Operational Program "Education and Lifelong 
Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program 
of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in 
knowledge society through the European Social Fund. DFKZ:  German Cancer Research Center. 
EMBRACE: Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans 
and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, 
Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS 
Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The 
Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and 
Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Ros Eeles is also 
supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer 
Research and The Royal Marsden NHS Foundation Trust. FCCC: The University of Kansas 
Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. 
A.K.G. was funded by R0 1CA140323, R01 CA214545, and by the Chancellors Distinguished 
Chair in Biomedical Sciences Professorship. FPGMX: FISPI05/2275 and Mutua Madrileña 
 19 
Foundation (FMMA). GC-HBOC: German Cancer Aid (grant no 110837, Rita K. Schmutzler) and 
the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig 
Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 
14505/2470, 14575/2470). GEMO: Ligue Nationale Contre le Cancer; the Association “Le cancer 
du sein, parlons-en!” Award, the Canadian Institutes of Health Research for the "CIHR Team in 
Familial Risks of Breast Cancer" program and the French National Institute of Cancer (INCa). 
GEORGETOWN: the Non-Therapeutic Subject Registry Shared Resource at Georgetown 
University (NIH/NCI grant P30-CA051008), the Fisher Center for Hereditary Cancer and Clinical 
Genomics Research, and Swing Fore the Cure. G-FAST: Bruce Poppe is a senior clinical 
investigator of FWO. Mattias Van Heetvelde obtained funding from IWT. HCSC: Spanish Ministry 
of Health PI15/00059, PI16/01292, and CB-161200301 CIBERONC from ISCIII (Spain), partially 
supported by European Regional Development FEDER funds. HEBCS: Helsinki University 
Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid 
Juselius Foundation. HEBON: the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, 
NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the 
Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and 
the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the registration teams of Dutch 
Cancer Registry (IKNL; S. Siesling, J. Verloop) and the Dutch Pathology database (PALGA; L. 
Overbeek) for part of the data collection. HRBCP:  Hong Kong Sanatorium and Hospital, Dr Ellen 
Li Charitable Foundation, The Kerry Group Kuok Foundation, National Institute of Health1R 
03CA130065, and North California Cancer Center. HUNBOCS: Hungarian Research Grants 
KTIA-OTKA CK-80745 and OTKA K-112228. ICO: The authors would like to particularly 
acknowledge the support of the Asociación Española Contra el Cáncer (AECC), the Instituto de 
Salud Carlos III (organismo adscrito al Ministerio de Economía y Competitividad) and “Fondo 
Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa” (PI10/01422, 
PI13/00285, PIE13/00022, PI15/00854, PI16/00563 and CIBERONC) and the Institut Català de 
 20 
la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338 and PERIS 
Project MedPerCan). IHCC: PBZ_KBN_122/P05/2004. ILUH: Icelandic Association “Walking for 
Breast Cancer Research” and by the Landspitali University Hospital Research Fund. INHERIT: 
Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” 
program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export 
Trade – grant # PSR-SIIRI-701. IOVHBOCS: Ministero della Salute and “5x1000” Istituto 
Oncologico Veneto grant. IPOBCS: Liga Portuguesa Contra o Cancro. kConFab:  The National 
Breast Cancer Foundation, and previously by the National Health and Medical Research Council 
(NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, 
Tasmania and South Australia, and the Cancer Foundation of Western Australia. MAYO: NIH 
grants CA116167, CA192393 and CA176785, an NCI Specialized Program of Research 
Excellence (SPORE) in Breast Cancer (CA116201),and a grant from the Breast Cancer Research 
Foundation. MCGILL: Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry 
of Economic Development, Innovation and Export Trade.  Marc Tischkowitz is supported by the 
funded by the European Union Seventh Framework Program (2007Y2013)/European Research 
Council (Grant No. 310018). MODSQUAD: MH CZ - DRO (MMCI, 00209805), MEYS - NPS I - 
LO1413 to LF and by the European Regional Development Fund and the State Budget of the 
Czech Republic (RECAMO,  CZ.1.05/2.1.00/03.0101) to LF, and by Charles University in Prague 
project UNCE204024 (MZ). MSKCC: the Breast Cancer Research Foundation, the Robert and 
Kate Niehaus Clinical Cancer Genetics Initiative, the Andrew Sabin Research Fund and a Cancer 
Center Support Grant/Core Grant (P30 CA008748). NAROD: 1R01 CA149429-01. NCI: the 
Intramural Research Program of the US National Cancer Institute, NIH, and by support services 
contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, 
MD.    NICCC:  Clalit Health Services in Israel,  the Israel Cancer Association and the Breast 
Cancer Research Foundation (BCRF), NY. NNPIO: the Russian Federation for Basic Research 
(grants 15-04-01744, 16-54-00055 and 17-54-12007). NRG Oncology:  U10 CA180868, NRG 
 21 
SDMC grant U10 CA180822, NRG Administrative Office and the NRG Tissue Bank (CA 27469), 
the NRG Statistical and Data Center (CA 37517) and the Intramural Research Program, NCI. 
OSUCCG:  Ohio State University Comprehensive Cancer Center. PBCS: Italian Association of 
Cancer Research (AIRC) [IG 2013 N.14477] and Tuscany Institute for Tumors (ITT) grant 2014-
2015-2016. SEABASS: Ministry of Science, Technology and Innovation, Ministry of Higher 
Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation. SMC: the Israeli 
Cancer Association. SWE-BRCA: the Swedish Cancer Society. UCHICAGO:  NCI Specialized 
Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 
1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment 
Industry Fund National Women's Cancer Research Alliance and the Breast Cancer research 
Foundation. OIO is an ACS Clinical Research Professor. UCLA: Jonsson Comprehensive Cancer 
Center Foundation; Breast Cancer Research Foundation. UCSF:  UCSF Cancer Risk Program 
and Helen Diller Family Comprehensive Cancer Center. UKFOCR: Cancer Researc h UK.  
UPENN: National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855; Breast Cancer 
Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for 
BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer 
Australia, National Breast Cancer Foundation.  WCP: Dr Karlan is funded by the American Cancer 
Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for 
Advancing Translational Sciences (NCATS), Grant UL1TR000124. 
Acknowledgements 
All the families and clinicians who contribute to the studies; Sue Healey, in particular taking on 
the task of  mutation classification with the late Olga Sinilnikova; Maggie Angelakos, Judi Maskiell, 
Gillian Dite, Helen Tsimiklis; members and participants in the New York site of the Breast Cancer 
Family Registry; members and participants in the Ontario Familial Breast Cancer Registry; Vilius 
Rudaitis and Laimonas Griškevičius;  Drs Janis Eglitis, Anna Krilova and Aivars Stengrevics; Yuan 
Chun Ding and Linda Steele  for their work in participant enrollment and biospecimen and data 
 22 
management; Bent Ejlertsen and Anne-Marie Gerdes for the recruitment and genetic counseling 
of participants; Alicia Barroso, Rosario Alonso and Guillermo Pita; Manoukian Siranoush, Bernard 
Peissel, Cristina Zanzottera, Milena Mariani, Daniela Zaffaroni, Bernardo Bonanni, Monica Barile, 
Irene Feroce, Mariarosaria Calvello, Alessandra Viel, Riccardo Dolcetti, Laura Ottini, Giuseppe 
Giannini, Laura Papi, Gabriele Lorenzo Capone, Liliana Varesco, Viviana Gismondi, Maria Grazia 
Tibiletti, Daniela Furlan, Antonella Savarese, Aline Martayan, Stefania Tommasi, Brunella Pilato; 
the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. Ms. JoEllen Weaver 
and Dr. Betsy Bove; Marta Santamariña, Ana Blanco, Miguel Aguado, Uxía Esperón and Belinda 
Rodríguez; IFE - Leipzig Research Centre for Civilization Diseases (Markus Loeffler, Joachim 
Thiery, Matthias Nüchter, Ronny Baber);  We thank all participants, clinicians, family doctors, 
researchers, and technicians for their contributions and commitment to the DKFZ study and the 
collaborating groups in Lahore, Pakistan (Muhammad U. Rashid, Noor Muhammad, Sidra Gull, 
Seerat Bajwa, Faiz Ali Khan, Humaira Naeemi, Saima Faisal, Asif Loya, Mohammed Aasim 
Yusuf) and Bogota, Colombia (Diana Torres, Ignacio Briceno, Fabian Gil). Genetic Modifiers of 
Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study is a study from the National Cancer 
Genetics Network UNICANCER Genetic Group, France. We wish to pay a tribute to Olga M. 
Sinilnikova, who with Dominique Stoppa-Lyonnet initiated and coordinated GEMO until she sadly 
passed away on the 30th June 2014. The team in Lyon (Olga Sinilnikova, Mélanie Léoné, Laure 
Barjhoux, Carole Verny-Pierre, Sylvie Mazoyer, Francesca Damiola, Valérie Sornin) managed the 
GEMO samples until the biological resource centre was transferred to Paris in December 2015 
(Noura Mebirouk, Fabienne Lesueur, Dominique Stoppa-Lyonnet). We want to thank all the 
GEMO collaborating groups for their contribution to this study: Coordinating Centre, Service de 
Génétique, Institut Curie, Paris, France: Muriel Belotti, Ophélie Bertrand, Anne-Marie Birot, Bruno 
Buecher, Sandrine Caputo, Anaïs Dupré, Emmanuelle Fourme, Marion Gauthier-Villars, Lisa 
Golmard, Claude Houdayer, Marine Le Mentec, Virginie Moncoutier, Antoine de Pauw, Claire 
Saule, Dominique Stoppa-Lyonnet, and Inserm U900, Institut Curie, Paris, France: Fabienne 
 23 
Lesueur, Noura Mebirouk.Contributing Centres : Unité Mixte de Génétique Constitutionnelle des 
Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard, Lyon, France: Nadia Boutry-
Kryza, Alain Calender, Sophie Giraud, Mélanie Léone. Institut Gustave Roussy, Villejuif, France: 
Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille. Centre Jean Perrin, 
Clermont–Ferrand, France: Yves-Jean Bignon, Nancy Uhrhammer. Centre Léon Bérard, Lyon, 
France: Valérie Bonadona, Christine Lasset. Centre François Baclesse, Caen, France: Pascaline 
Berthet, Laurent Castera, Dominique Vaur. Institut Paoli Calmettes, Marseille, France: Violaine 
Bourdon, Catherine Noguès, Tetsuro Noguchi, Cornel Popovici, Audrey Remenieras, Hagay 
Sobol. CHU Arnaud-de-Villeneuve, Montpellier, France: Isabelle Coupier, Pascal Pujol. Centre 
Oscar Lambret, Lille, France: Claude Adenis, Aurélie Dumont, Françoise Révillion. Centre Paul 
Strauss, Strasbourg, France: Danièle Muller. Institut Bergonié, Bordeaux, France: Emmanuelle 
Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Michel Longy, Nicolas Sevenet, Institut 
Claudius Regaud, Toulouse, France: Laurence Gladieff, Rosine Guimbaud, Viviane Feillel, 
Christine Toulas. CHU Grenoble, France: Hélène Dreyfus, Christine Dominique Leroux, Magalie 
Peysselon, Rebischung. CHU Dijon, France: Amandine Baurand, Geoffrey Bertolone, Fanny 
Coron, Laurence Faivre, Caroline Jacquot, Sarab Lizard. CHU St-Etienne, France: Caroline 
Kientz, Marine Lebrun, Fabienne Prieur. Hôtel Dieu Centre Hospitalier, Chambéry, France: 
Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice, France: Véronique Mari. CHU Limoges, 
France: Laurence Vénat-Bouvet. CHU Nantes, France: Stéphane Bézieau, Capucine Delnatte. 
CHU Bretonneau, Tours and Centre Hospitalier de Bourges France: Isabelle Mortemousque. 
Groupe Hospitalier Pitié-Salpétrière, Paris, France: Chrystelle Colas, Florence Coulet, Florent 
Soubrier, Mathilde Warcoin. CHU Vandoeuvre-les-Nancy, France: Myriam Bronner, Johanna 
Sokolowska. CHU Besançon, France: Marie-Agnès Collonge-Rame, Alexandre Damette. CHU 
Poitiers, Centre Hospitalier d’Angoulême and Centre Hospitalier de Niort, France: Paul Gesta. 
Centre Hospitalier de La Rochelle : Hakima Lallaoui. CHU Nîmes Carémeau, France : Jean 
Chiesa. CHI Poissy, France: Denise Molina-Gomes. CHU Angers, France : Olivier Ingster; Ilse 
 24 
Coene en Brecht Crombez; Ilse Coene and Brecht Crombez; Alicia Tosar and Paula Diaque; Drs 
.Sofia Khan, Taru A. Muranen, Carl Blomqvist,  Irja Erkkilä and Virpi Palola; The Hereditary Breast 
and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following 
Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: M.A. 
Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, S. Verhoef, M.K. Schmidt, N.S. Russell, D.J. 
Jenner; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, A.M.W. van den Ouweland, M.J. 
Hooning, C. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, NL: 
C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, T.C.T.E.F. van Cronenburg; 
Radboud University Nijmegen Medical Center, NL: C.M. Kets, A.R. Mensenkamp; University 
Medical Center Utrecht, NL: M.G.E.M. Ausems, R.B. van der Luijt, C.C. van der Pol; Amsterdam 
Medical Center, NL: C.M. Aalfs, T.A.M. van Os; VU University Medical Center, Amsterdam, NL: 
J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, NL: E.B. Gómez-
Garcia, M.J. Blok; University Medical Center Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, 
M.J. Mourits, G.H. de Bock; The Netherlands Foundation for the detection of hereditary tumours, 
Leiden, NL: H.F. Vasen; The Netherlands Comprehensive Cancer Organization (IKNL): S. 
Siesling, J.Verloop; The Dutch Pathology Registry (PALGA): L.I.H. Overbeek; Hong Kong 
Sanatorium and Hospital; the Hungarian Breast and Ovarian Cancer Study Group members 
(Janos Papp, Aniko Bozsik, Timea Pocza, Zoltan Matrai, Miklos Kasler, Judit Franko, Maria 
Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute 
of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this 
study; the Oncogenetics Group (VHIO) and the High Risk and Cancer Prevention Unit of the 
University Hospital Vall d’Hebron, and the Cellex Foundation for providing research facilities and 
equipment; the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella; the ICO 
Hereditary Cancer Program team led by Dr. Gabriel Capella; Dr Martine Dumont for sample 
management and skillful assistance; Ana Peixoto, Catarina Santos and Pedro Pinto; members of 
the Center of Molecular Diagnosis, Oncogenetics Department and Molecular Oncology Research 
 25 
Center of Barretos Cancer Hospital; Heather Thorne, Eveline Niedermayr, all the kConFab 
research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow 
Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, 
Cancer Australia, and the National Institute of Health (USA)) for their contributions to this 
resource, and the many families who contribute to kConFab;  the KOBRA Study Group; Csilla 
Szabo (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 
USA); Lenka Foretova and Eva Machackova (Department of Cancer Epidemiology and Genetics, 
Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic); and Michal Zikan, Petr 
Pohlreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and 
Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic); 
Anne Lincoln, Lauren Jacobs; the NICCC National Familial Cancer Consultation Service team led 
by Sara Dishon, the lab team led by Dr. Flavio Lejbkowicz, and the research field operations team 
led by Dr. Mila Pinchev; the investigators of the Australia New Zealand NRG Oncology group; 
members and participants in the Ontario Cancer Genetics Network; Leigha Senter, Kevin Sweet, 
Caroline Craven, Julia Cooper,  and Michelle O'Conor; Yip Cheng Har, Nur Aishah Mohd Taib, 
Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and 
doctors involved in the MyBrCa Study for assistance in patient recruitment, data collection and 
sample preparation, Philip Iau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples 
from the Singapore Breast Cancer Study and the HUKM-HKL Study respectively; the Meirav 
Comprehensive breast cancer center team at the Sheba Medical Center; Christina Selkirk; Åke 
Borg, Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller,  Ulf 
Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta 
Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: 
Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, 
Johanna Rantala; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, 
Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellström Pigg, 
 26 
Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmalm, Sigrun 
Liedgren; Cecilia Zvocec, Qun Niu; Joyce Seldon and Lorna Kwan; Dr. Robert Nussbaum, Beth 
Crawford, Kate Loranger, Julie Mak, Nicola Stewart,  Robin Lee, Amie Blanco and Peggy Conrad 
and Salina Chan; Simon Gayther, Susan Ramus, Paul Pharoah, Carole Pye, Patricia Harrington 
and Eva Wozniak; Geoffrey Lindeman, Marion Harris, Martin Delatycki,  Sarah Sawyer, Rebecca 



























1. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-
oophorectomy in BRCA1 and BRCA2 PSV carriers: a prospective cohort study. Lancet 
Oncol 2006;7(3):223-9. 
2. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 
or BRCA2 PSV carriers with cancer risk and mortality. JAMA;304(9):967-75. 
3. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. 
Curr Opin Obstet Gynecol 2007;19(1):27-30. 
4. Domchek SM, Stopfer JE, Rebbeck TR. Bilateral risk-reducing oophorectomy in BRCA1 and 
BRCA2 PSV carriers. J Natl Compr Canc Netw 2006;4(2):177-82. 
5. Rebbeck T, Kauff N, Domchek S. Cancer Risk Reduction in BRCA1 and BRCA2 PSV 
Carriers: Meta-Analysis of Risk-Reduction Estimates Associated with Risk-Reducing 
Salpingo-Oophorectomy Submitted 2008. 
6. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy 
on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and 
BRCA2 PSV carriers: the PROSE Study Group. J Clin Oncol 2005;23(31):7804-10. 
7. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated 
with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 PSV carriers. J Natl Cancer 
Inst 2009;101(2):80-7. 
8. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 
29,700 families with BRCA1 or BRCA2 PSVs. Hum Mutat 2018;39(5):593-620. 
 28 
9. Chenevix-Trench G, Milne RL, Antoniou AC, et al. An international initiative to identify 
genetic modifiers of cancer risk in BRCA1 and BRCA2 PSV carriers: the Consortium of 
Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 
2007;9(2):104. 
10. Fackenthal JD, Sveen L, Gao Q, et al. Complete allelic analysis of BRCA1 and BRCA2 
variants in young Nigerian breast cancer patients. J Med Genet 2005;42(3):276-81. 
11. Fackenthal JD, Zhang J, Zhang B, et al. High prevalence of BRCA1 and BRCA2 PSVs in 
unselected Nigerian breast cancer patients. Int J Cancer 2012;131(5):1114-23. 
12. Francies FZ, Wainstein T, De Leeneer K, et al. BRCA1, BRCA2 and PALB2 PSVs and 
CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal 
and/or triple negative breast cancer. BMC Cancer 2015;15:912. 
13. Gao Q, Tomlinson G, Das S, et al. Prevalence of BRCA1 and BRCA2 PSVs among clinic-
based African American families with breast cancer. Hum Genet 2000;107(2):186-91. 
14. Diez O, Pelegrí A, Gadea N, et al. Novel BRCA1 deleterious PSV (c.1949_1950delTA) in a 
woman of Senegalese descent with triple-negative early-onset breast cancer. Oncol Lett 
2011;2(6):1287-1289. 
15. Awadelkarim KD, Aceto G, Veschi S, et al. BRCA1 and BRCA2 status in a Central Sudanese 
series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. 
Breast Cancer Res Treat 2007;102(2):189-99. 
16. Biunno I, Aceto G, Awadelkarim KD, et al. BRCA1 point PSVs in premenopausal breast 
cancer patients from Central Sudan. Fam Cancer 2014;13(3):437-44. 
17. Luyeye Mvila G, Postema S, Marchal G, et al. From the set-up of a screening program of 
breast cancer patients to the identification of the first BRCA PSV in the DR Congo. BMC 
Public Health 2014;14:759. 
 29 
18. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, et al. BRCA1 sequence variations in 160 
individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer 
Group. Am J Hum Genet 1997;60(5):1021-30. 
19. Zhang J, Fackenthal JD, Huo D, et al. Searching for large genomic rearrangements of the 
BRCA1 gene in a Nigerian population. Breast Cancer Res Treat 2010;124(2):573-7. 
20. Zhang B, Fackenthal JD, Niu Q, et al. Evidence for an ancient BRCA1 PSV in breast cancer 
patients of Yoruban ancestry. Fam Cancer 2009;8(1):15-22. 
21. van der Merwe NC, Hamel N, Schneider SR, et al. A founder BRCA2 PSV in non-Afrikaner 
breast cancer patients of the Western Cape of South Africa. Clin Genet 2012;81(2):179-84. 
22. Elimam AA, Aabdein MEMM, Eldeen MEM, et al. Monoallelic characteristic-bearing 
heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer. BMC 
Med Genet 2017;18(1):85. 
23. Zhang J, Fackenthal JD, Zheng Y, et al. Recurrent BRCA1 and BRCA2 PSVs in breast 
cancer patients of African ancestry. Breast Cancer Res Treat 2012;134(2):889-94. 
24. Zoure AA, Slaoui M, Bambara HA, et al. BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), 
c.798_799delTT and 943ins10 (exon11) PSVs in Burkina Faso. J Public Health Afr 
2018;9(1):663. 
25. Zheng Y, Walsh T, Gulsuner S, et al. Inherited Breast Cancer in Nigerian Women. J Clin 
Oncol 2018:JCO2018783977. 
26. Arena J, Smith S, Plewinska M, et al. BRCA1 PSVs in African-American women. . American 
Journal of Human Genetics 1996(A34):169. 
27. Arena J, Baumbach L, Smith S, et al. BRCA1 PSV analysis in 20 at-risk African-American 
families supports a low frequency of germ-line PSV. American Journal of Human Genetics 
1998(A62):325. 
 30 
28. Gao Q, Sveen L, Cummings S, et al. Contribution of recurrent BRCA1 (B1) and BRCA2 (B2) 
PSVs to breast cancer in African Americans (AA) women. Proceedings of the American 
Association for Cancer Research 1998;39:475. 
29. Kedar‐Barnes I, Devilee P, Meijers‐Heijboer H, et al. Intronic BRCA1 PSVs in two highly 
affected kindreds. American Journal of Human Genetics 2000;67(99):A484. 
30. Sutphen R, Ferlita T. Inherited breast/ovarian cancer in African‐American  . . American 
Journal of Human Genetics 1999;65 (Suppl):A325. 
31. Whitfield-Broome C, Dunston G, Brody L. BRCA2 PSVs in African Americans. Proceedings 
of the American Association of Cancer Research 1999;40:269. 
32. Arena J, Smith S, Vincek V, et al. A BRCA1 founder PSV in African Americans. American 
Journal of Human Genetics 1997;61 (Suppl):A14. 
33. Gayol L, Scholl T, Basterrechea H, et al. BRCA1 PSV analysis in at-risk African-American 
families: Results and implications. American Journal of Human Genetics 1999;65(4):A127. 
34. Dangel J, Wagner-Costalas J, Bove B, et al. Novel germline BRCA1 PSV (155del4) in an 
African American with early-onset breast cancer. Human PSV 1999;14(6):545. 
35. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 PSVs in primary breast and ovarian 
carcinomas. Science 1994;266(5182):120-2. 
36. Ganguly T, Dhulipala R, Godmilow L, et al. High throughput fluorescence-based 
conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 PSVs 
and an overall low incidence of BRCA2 PSVs in high-risk BRCA1-negative breast cancer 
families. Human Genetics 1998;102(5):549-56. 
37. Gao Q, Neuhausen S, Cummings S, et al. Recurrent germ-line BRCA1 PSVs in extended 
African American families with early-onset breast cancer. American Journal of Human 
Genetics 1997;60(5):1233-6. 
38. Castilla LH, Couch FJ, Erdos MR, et al. PSVs in the BRCA1 gene in families with early-
onset breast and ovarian cancer. Nat Genet 1994;8(4):387-91. 
 31 
39. Kanaan Y, Kpenu E, Utley K, et al. Inherited BRCA2 PSVs in African Americans with breast 
and/or ovarian cancer: a study of familial and early onset cases. Human Genetics 
2003;113(5):452-60. 
40. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA PSVs in young black women 
with breast cancer residing in Florida. Cancer 2015;121(23):4173-80. 
41. Martin SE, Sausen M, Joseph A, et al. BRCA1 E1644X: a deleterious PSV in an African 
American individual with early onset breast cancer. Breast Cancer Res Treat 
2009;113(2):393-5. 
42. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian 
cancer susceptibility gene BRCA1. Science 1994;266(5182):66-71. 
43. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of 
high-risk women: a comparative analysis of BRCA1 and BRCA2 PSVs in American families 
of European and African ancestry. JAMA 2005;294(15):1925-33. 
44. Olopade OI, Fackenthal JD, Dunston G, et al. Breast cancer genetics in African Americans. 
Cancer 2003;97(1 Suppl):236-45. 
45. Panguluri RC, Brody LC, Modali R, et al. BRCA1 PSVs in African Americans. Human 
Genetics 1999;105(1-2):28-31. 
46. Shen D, Wu Y, Subbarao M, et al. PSV analysis of BRCA1 gene in African-American 
patients with breast cancer. Journal of the National Medical Association 2000;92(1):29-35. 
47. Lynce F, Smith KL, Stein J, et al. Deleterious BRCA1/2 PSVs in an urban population of 
Black women. Breast Cancer Res Treat 2015;153(1):201-9. 
48. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 PSV carriers in 5 US 
racial/ethnic groups. JAMA 2007;298(24):2869-76. 
49. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 PSVs in women of different 
ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 
2009;115(10):2222-33. 
 32 
50. Pal T, Permuth-Wey J, Holtje T, et al. BRCA1 and BRCA2 PSVs in a study of African 
American breast cancer patients. Cancer Epidemiol Biomarkers Prev 2004;13(11 Pt 
1):1794-9. 
51. Pal T, Vadaparampil S, Betts J, et al. BRCA1/2 in high-risk African American women with 
breast cancer: providing genetic testing through various recruitment strategies. Genet Test 
2008;12(3):401-7. 
52. Haffty BG, Choi DH, Goyal S, et al. Breast cancer in young women (YBC): prevalence of 
BRCA1/2 PSVs and risk of secondary malignancies across diverse racial groups. Ann Oncol 
2009;20(10):1653-9. 
53. Churpek JE, Walsh T, Zheng Y, et al. Inherited predisposition to breast cancer among 
African American women. Breast Cancer Res Treat 2015;149(1):31-9. 
54. Castilla LH, Couch FJ, Erdos MR, et al. PSVs in the BRCA1 gene in families with early-
onset breast and ovarian cancer. Nat Genet 1994;8(4):387-91. 
55. Donenberg T, Lunn J, Curling D, et al. A high prevalence of BRCA1 PSVs among breast 
cancer patients from the Bahamas. Breast Cancer Res Treat 2011;125(2):591-6. 
56. Akbari MR, Donenberg T, Lunn J, et al. The spectrum of BRCA1 and BRCA2 PSVs in breast 
cancer patients in the Bahamas. Clin Genet 2014;85(1):64-7. 
57. Donenberg T, Ahmed H, Royer R, et al. A Survey of BRCA1, BRCA2, and PALB2 PSVs in 
women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat 
2016;159(1):131-8. 
58. Janavičius R. Founder BRCA1/2 PSVs in the Europe: implications for hereditary breast-
ovarian cancer prevention and control. EPMA J 2010;1(3):397-412. 
59. Arai M, Yokoyama S, Watanabe C, et al. Genetic and clinical characteristics in Japanese 
hereditary breast and ovarian cancer: first report after establishment of HBOC registration 
system in Japan. J Hum Genet 2018;63(4):447-457. 
 33 
60. Rebbeck TR, Friebel TM, Mitra N, et al. Inheritance of deleterious PSVs at both BRCA1 and 
BRCA2 in an international sample of 32,295 women. Breast Cancer Res 2016;18(1):112. 
61. Oluwagbemiga LA, Oluwole A, Kayode AA. Seventeen years after BRCA1: what is the 
BRCA PSV status of the breast cancer patients in Africa? - a systematic review. 
Springerplus 2012;1(1):83. 
62. Laitman Y, Feng BJ, Zamir IM, et al. Haplotype analysis of the 185delAG BRCA1 PSV in 
ethnically diverse populations. Eur J Hum Genet 2013;21(2):212-6. 
63. Slaoui M, Razine R, Ibrahimi A, et al. Breast cancer in Morocco: a literature review. Asian 
Pac J Cancer Prev 2014;15(3):1067-74. 
64. Vanderpuye V, Grover S, Hammad N, et al. An update on the management of breast cancer 
in Africa. Infect Agent Cancer 2017;12:13. 
65. American Cancer Society. Cancer Facts & Figures for African Americans 2016-2018 . In. 
Atlanta: American Cancer Society; 2016. 
66. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, et al. The nonsense-mediated mRNA 
decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination 
codons. Human Molecular Genetics 2002;11(23):2805-14. 
67. Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, et al. The Icelandic founder PSV BRCA2 
999del5: analysis of expression. Breast Cancer Res 2004;6(4):R284-90. 
68. Ware MD, DeSilva D, Sinilnikova OM, et al. Does nonsense-mediated mRNA decay explain 
the ovarian cancer cluster region of the BRCA2 gene? Oncogene 2006;25(2):323-8. 
69. Buisson M, Anczukow O, Zetoune AB, et al. The 185delAG PSV (c.68_69delAG) in the 
BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 
2006;27(10):1024-9. 
70. Anczukow O, Ware MD, Buisson M, et al. Does the nonsense-mediated mRNA decay 






Table 1. Ten Most Common PSVs in BRCA1 (GenBank reference sequence: NG_005905.2)  or BRCA2 














Countries in Which 
PSV Has Been 
Reported in SRAA 
individuals 
Continent on 
Which PSV Has 








c.815_824dup 100 155 65% Senegal, Bahamas, Ivory 





c.4357+1G>A 73 88 83% Bahamas, USA North America, 
Europe 




c.4986+6T>C 35 45 78% Bahamas, USA, Sudan North America, 
Europe, South 
America 




c.303T>G 26 34 76% Nigeria North America, 
Europe 
c.190T>G 19 30 63% USA North America, 
Europe 
c.5467+1G>A 16 25 64% USA North America, 
Europe, Asia 

















Countries in Which 
PSV Has Been 
Reported in SRAA 
individuals 
Continent on 
Which PSV Has 

















c.5616_5620del 18 23 78% USA North America, 
Europe 




c.4552del 11 12 92% USA North America 
c.9253dup 10 69 14% USA North America, 
Europe, Asia 
c.5771_5774del 9 18 50% South Africa North America, 
Europe 
c.2402_2412del 7* 7 100% Nigeria 
 
c.2957_2958insG 7* 8 88% USA, Nigeria North America 
 









Table 2. Determination of Continent of Origin for PSVs in BRCA1 (GenBank reference 
sequence: NG_005905.2)  or BRCA2 (GenBank reference sequence NG_012772.3) Identified 
in Self-Reported African Ancestry Individuals, Including Likely African (100%), Possibly 
African (50-99%), Unlikely African (25-49%), and Likely Non-African (<25%). 
 
 BRCA1 BRCA2  
Determination N % N % Total 
Likely African 50 30.5% 65 37.6% 115 
Possibly African 33 20.1% 26 15.0% 59 
Unlikely African 19 11.6% 16 9.2% 35 
Likely Non-African 62 37.8% 66 38.7% 128 
Total 164 100% 173 100% 337 
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Table 3: Characteristics of BRCA1 (GenBank reference sequence: NG_005905.2)  PSVs in the CIMBA Database[8], By Unique 
PSV, Compared to Likely or Possible PSVs of African Origin. 
  
N=1,650 CIMBA PSVs  
(All Ethnicities) 




  N % N % P-value* 
 Large Deletion (DL) 130 7.9 10 6.1 0.749 
 Large Duplication (DP) 27 1.6 2 1.2 >0.999 
 Frameshift (FS) 948 57.5 66 40.2 <0.0001 
PSV Type In-Frame Deletion (IFD) 1 <0.1 4 2.4 <0.0001 
 Missense (MS) 46 2.8 9 5.5 0.078 
 Nonsense (NS) 313 19.0 40 24.4 0.081 
 Splice (SP) 166 10.1 20 12.2 0.259 
 
Multiple Types (including those listed 
above)/Unknown 
20 1.1 13 7.9 <0.0001 
PSV Effect No RNA 21 1.3 5 3.0 0.055 
 Premature Termination Codon (PTC) 1,331 81.0 95 57.9 <0.0001 
 Unknown/Other 298 18.0 64 39.0 <0.0001 
 Nonsense-Mediated Decay (NMD)** 1,213 73.9 84 51.2 <0.0001 
 No NMD 58 3.5 2 1.2 0.229 
 Re-Initiation 4 0.2 2 1.2 0.080 
 NMD/Re-initiation 60 3.7 8 4.9 0.492 
 Unknown/Other 294 17.8 68 41.5 <0.0001 
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N=1,650 CIMBA PSVs  
(All Ethnicities) 




  N % N % P-value* 
PSV Class 1 1,298 78.6 99 60.6 0.756 
 2 112 6.8 10 6.1  
 3 240 14.6 19 11.6  
 Unknown   36 22.0  
*P-values from Fisher’s Exact Test reflect the comparison of All Ethicities vs Likely or Possible African PSVs, for the specific 







Table 4: Characteristics of BRCA2 (GenBank reference sequence NG_012772.3) PSVs in the CIMBA Database[8], By Unique 
PSV, Compared to Likely and Possible PSVs of African Origin. 
  
N=1,731 CIMBA PSVs  
(All Ethnicities) 




  N % N % P-Value* 
 Large Deletion (DL) 34 1.9 1 0.01 0.003 
 Large Duplication (DP) 11 0.6 0 0.0 NE 
 Frameshift (FS) 1,141 65.9 106 61.3 <0.0001 
PSV Type In-Frame Deletion (IFD) 2 0.1 0 0.0 NE 
 Missense (MS) 13 0.8 1 0.01 NE 
 Nonsense (NS) 380 22.0 47 27.2 0.617 
 Splice (SP) 131 7.6 8 4.6 0.062 
 
Multiple Types (including those listed 
above) 
19 1.1 10 5.8 <0.0001 
PSV Effect No RNA 6 0.3 0 0.0 NE 
 Premature Termination Codon (PTC) 1,542 89.0 132 76.3 <0.0001 
 Unknown/Other 183 10.6 41 23.7 <0.0001 
 Nonsense-Mediated Decay (NMD)**  1,523 88.0 132 76.3 <0.0001 
 No NMD 16 0.9 0 0 NE 
 Re-Initiation 0 0.0 0 0 NE 
 NMD/Re-initiation 0 0.0 0 0 NE 
 Unknown/Other 187 10.7 41 23.7 <0.0001 
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N=1,731 CIMBA PSVs  
(All Ethnicities) 




  N % N % P-Value* 
PSV Class 1 1,529 88.3 131 75.7 <0.0001 
 2 36 2.1 0 0  
 3 167 9.6 6 3.5  
 Unknown   36 20.8  
*P-values from Fisher’s Exact Test reflect the comparison of All Ethicities vs Likely or Possible African PSVs, for the specific 
mutation group vs. all other mutations.  
**References [66-70] 
NE: not estimable. 
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Include: 
 Additional articles from 
references (n=5) 
 Abstracts/supplements from 
references (n=8) 
 Poster from conference (n=1) 
 
Figure 1: Summary of Literature Review Used in This Report for BRCA1 (GenBank reference 





Literature Search Result:  
852 Articles 




Abstract or Manuscript 
review for inclusion 
 
Include n=33 Articles 
reporting original data for 
BRCA1/BRCA2 
Exclude: 
 Reports from North Africa 
(n=44) 
 Male Prostate Cancer (n=11) 
 No African Ancestry (n=63) 
 No deleterious BRCA1/2 PSVs 
reported (n=149) 
 Review Articles or Not 
Applicable (n=33) 
 Afrikaner population (n=3) 
 
Include n=47 Articles 
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Figure 2: BRCA1 (GenBank reference sequence: NG_005905.2) PSVs by Determination of 
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Figure 3: BRCA2 (GenBank reference sequence NG_012772.3) PSVs by Determination of African 
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